
In 1L cHL Stg III or IV, #Nivolumab + AVD is now ✅ @US_FDA approved based off @SWOG 1826 (vs. #Brentuximab + AVD): - mPFS not reached. PFS HR: 0.42 - ⬆️ neuropathy & discontinuation w/ Bv-AVD - Adopted in clinical practice since its presentation. Now SoC #lysm #HemeTwitter



























